Inactive Instrument

Zynerba Pharmaceuticals, Inc.

Equities

ZYNE

US98986X1090

Biotechnology & Medical Research

Thinking about buying stock in Zynerba Pharmaceuticals, Taysha Gene Therapies, Novo Integrated Sciences, Design Therapeutics, or Limbach Holdings?

August 17, 2023 at 09:32 am EDT

NEW YORK, Aug. 17, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZYNE, TSHA, NVOS, DSGN, and LMB.

InvestorsObserver (PRNewsfoto/InvestorsObserver)

To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

ZYNE: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=ZYNE&prnumber=081720230
TSHA: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=TSHA&prnumber=081720234
NVOS: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=NVOS&prnumber=081720234
DSGN: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=DSGN&prnumber=081720234
LMB: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=LMB&prnumber=081720234

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.

InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.

View original content to download multimedia:https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-zynerba-pharmaceuticals-taysha-gene-therapies-novo-integrated-sciences-design-therapeutics-or-limbach-holdings-301903629.html

SOURCE InvestorsObserver

Latest news about Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index	23-10-12	CI
Harmony Biosciences Holdings Completes Acquisition of Zynerba Pharmaceuticals	23-10-11	MT
Harmony Biosciences Holdings, Inc. completed the acquisition of Zynerba Pharmaceuticals, Inc..	23-10-09	CI
Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index	23-09-28	CI
Harmony Biosciences Says its Xylophone Acquisition Unit Extends Tender Offer for Zynerba Pharmaceuticals to Oct. 10	23-09-27	MT
North American Morning Briefing : Treasury Yields -2-	23-08-17	DJ
Canaccord Genuity Downgrades Zynerba Pharmaceuticals to Hold From Buy, Adjusts Price Target to $1.11 From $10	23-08-16	MT
North American Morning Briefing : Stock Futures -2-	23-08-16	DJ
HC Wainwright Downgrades Zynerba Pharmaceuticals to Neutral From Buy	23-08-15	MT
Health Care Up on Drug Developments -- Health Care Roundup	23-08-14	DJ
Sector Update: Health Care Stocks Higher Late Afternoon	23-08-14	MT
Sector Update: Health Care Stocks Higher on Monday Afternoon	23-08-14	MT
Top Midday Gainers	23-08-14	MT
Zynerba Pharmaceuticals Shares Soar on Harmony Biosciences Acquisition Deal	23-08-14	MT
Sector Update: Health Care Stocks Edge Higher Premarket Monday	23-08-14	MT
Sector Update: Health Care	23-08-14	MT
Transcript : Harmony Biosciences Holdings, Inc., Zynerba Pharmaceuticals, Inc. - M&A Call	23-08-14
Harmony Biosciences Agrees to Acquire Zynerba Pharmaceuticals	23-08-14	MT
Harmony Biosciences To Acquire Zynerba Pharmaceuticals, Inc.	23-08-14	RE
Zynerba Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Harmony Biosciences Holdings, Inc. entered into a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. ) for $63.7 million.	23-08-13	CI
Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from Russell Microcap Value Index	23-06-23	CI
Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from Russell 3000E Value Index	23-06-23	CI
Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from Russell 3000E Index	23-06-23	CI
Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from Russell Microcap Index	23-06-23	CI

Chart Zynerba Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Zynerba Pharmaceuticals, Inc. is primarily engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The Company is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 deletion syndrome (22q). It is focused on using cannabinoids for treating behavioral symptoms of FXS and 22q. The Company is developing Zygel (ZYN002), a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of tetrahydrocannabinol (THC). It uses a patent protected formulation containing ethanol and propylene glycol as solubilizing agents and Transcutol HP as a permeation enhancer. Zygel is an investigational drug product in development for the potential treatment of behavioral symptoms associated with FXS, 22q, and autism spectrum disorder (ASD).

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+2.19%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+11.46%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.61%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.06%	18.12B
MEDPACE HOLDINGS, INC.	+30.73%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.44%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.46%	11B

Other Biotechnology & Medical Research